Nkarta Inc (NKTX)

$9.6

+0.1

(+1.05%)

Market is closed - opens 8 PM, 26 Feb 2024

Insights on Nkarta Inc

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 242.0% return, outperforming this stock by 323.4%

Performance

  • $9.50
    $9.95
    $9.60
    downward going graph

    1.04%

    Downside

    Day's Volatility :4.52%

    Upside

    3.52%

    downward going graph
  • $1.28
    $12.20
    $9.60
    downward going graph

    86.67%

    Downside

    52 Weeks Volatility :89.51%

    Upside

    21.31%

    downward going graph

Returns

PeriodNkarta IncSector (Health Care)Index (Russel 2000)
3 Months
266.41%
12.8%
0.0%
6 Months
439.33%
11.6%
0.0%
1 Year
125.35%
15.1%
-6.4%
3 Years
-81.39%
28.9%
-22.6%

Highlights

Market Capitalization
470.6M
Book Value
$6.05
Earnings Per Share (EPS)
-2.5
Wall Street Target Price
15.63
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-18.61%
Return On Equity TTM
-35.15%
Revenue TTM
385.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
-36.2M
EBITDA
-131.1M
Diluted Eps TTM
-2.5
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.42
EPS Estimate Next Year
-2.49
EPS Estimate Current Quarter
-0.67
EPS Estimate Next Quarter
-0.71

Analyst Recommendation

Buy
    93%Buy
    6%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Nkarta Inc(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
15
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 62.81%

Current $9.60
Target $15.63

Technicals Summary

Sell

Neutral

Buy

Nkarta Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Nkarta Inc
Nkarta Inc
15.66%
439.33%
125.35%
-81.39%
-79.96%
Moderna, Inc.
Moderna, Inc.
-4.6%
-14.37%
-30.73%
-33.38%
345.54%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.48%
18.04%
29.62%
113.96%
133.41%
Novo Nordisk A/s
Novo Nordisk A/s
17.34%
33.21%
74.36%
242.01%
399.49%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.6%
24.03%
49.67%
98.17%
130.83%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Nkarta Inc
Nkarta Inc
NA
NA
NA
-2.42
-0.35
-0.19
NA
6.05
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.46
-0.22
-0.07
NA
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
27.77
27.77
1.97
44.85
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
45.7
45.7
4.49
3.31
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.77
30.77
0.58
16.74
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Nkarta Inc
Nkarta Inc
Buy
$470.6M
-79.96%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$37.9B
345.54%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$105.9B
133.41%
27.77
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.7B
399.49%
45.7
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$110.2B
130.83%
30.77
36.68%

Institutional Holdings

  • RA Capital Management, LLC

    15.91%
  • T. Rowe Price Investment Management,Inc.

    9.17%
  • NEA Management Company, LLC

    7.27%
  • Adage Capital Partners Gp LLC

    7.03%
  • BlackRock Inc

    5.89%
  • Samsara BioCapital, LLC

    5.84%

Corporate Announcements

  • Nkarta Inc Earnings

    Nkarta Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

nkarta therapeutics seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies. nkarta was founded on the proprietary, robust and well characterized natural killer (nk) cell expansion technology pioneered by dario campana. the company is focused on leveraging the natural potent power of nk cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. nkarta is combining its nk expansion platform technology with proprietary cell engineering technologies to build differentiated autologous and allogeneic cell therapy candidates for the treatment of cancer. founded in 2015, the company’s investors include sr one, nea and novo ventures. for more information, please visit the company’s website at www.nkartatx.com.

Organization
Nkarta Inc
Employees
167
CEO
Mr. Paul J. Hastings
Industry
Health Technology

FAQs